

FLT1

Recombinant Human VEGFR-1 / Fc Chimera, soluble

Catalog No.	CRF105A CRF105B	Quantity:	10 µg 50 µg
Alternate Names:	Vascular Endothelial Growth Factor Receptor-1, Fms-like tyrosine kinase 1, FLT-1		
Description:	<p>Recombinant human soluble Vascular Endothelial Growth Factor Receptor-1 was fused with the Fc part of human IgG₁. The recombinant mature sVEGFR-1_{D1-7}/Fc is a disulfide-linked homodimeric protein. The soluble receptor protein consists of all 7 extracellular domains (Met1-Thr751), which contain all the information necessary for high affinity ligand binding.</p> <p>Endothelial cells express three different vascular endothelial growth factor (VEGF) receptors, belonging to the family of receptor tyrosine kinases (RTKs). They are named VEGFR-1 (Flt-1), VEGFR-2 (KDR/Flk-1), and VEGFR-3 (Flt-4). Their expression is almost exclusively restricted to endothelial cells, but VEGFR-1 can also be found on monocytes. All VEGF-receptors have seven immunoglobulin-like extracellular domains, a single transmembrane region and an intracellular split tyrosine kinase domain. VEGFR-2 has a lower affinity for VEGF than the Flt-1 receptor, but a higher signaling activity. Mitogenic activity in endothelial cells is mainly mediated by VEGFR-2 leading to their proliferation. Differential splicing of the flt-1 gene leads to the formation of a secreted, soluble variant of VEGFR-1 (sVEGFR-1). No naturally occurring, secreted forms of VEGFR-2 have so far been reported. The binding of VEGF₁₆₅ to VEGFR-2 is dependent on heparin.</p>		
UniProt ID:	P17948		
Gene ID:	2321		
Source:	Insect cells		
Molecular Weight:	130 kDa, (954 aa) monomer		
Formulation:	Lyophilized from PBS, pH 7.4.		
Purity:	> 90%, by SDS-PAGE and visualized by silver stain		
Endotoxin Level:	< 0.1 EU/µg		
Biological Activity:	The activity of sVEGFR-1/Fc was determined by its ability to inhibit the VEGF-dependent proliferation of human umbilical vein endothelial cells.		
Reconstitution:	Centrifuge vial prior to opening. The lyophilized sVEGFR-1/Fc is soluble in water and most aqueous buffers. The lyophilized sVEGFR-1/Fc should be reconstituted in PBS or medium to a concentration ≥ 50 µg/ml.		
Storage & Stability:	Lyophilized samples are stable for greater than six months at -20°C to -80°C. Reconstituted sVEGFR-1/Fc should be stored in working aliquots at -20°C to -80°C. Avoid repeated freeze-thaw cycles.		



Amino Acid Sequence: SKLKDPELSL KGTQHIMQAG QTLHLQCRGE AAHKWSLPPEM VSKESEERLSI
TKSACGRNGK QFCSTLTLNT AQANHTGFYS CKYLAVPTSK KKETESAIYI
FISDTGRPFV EMYSEIPEII HMTEGRELVI PCRVTSPNIT VTLKKFPLDT LIPDGKRIIW
DSRKGFIIISN ATYKEIGLLT CEATVNGHLY KTNYLTHRQT NTIIDVQIST PRPVKLLRGH
TLVLNCTATT PLNTRVQMTW SYPDEKNKRA SVRRRIDQSN SHANIFYSVL
TIDKMQNKDK GLYTCRVRSG PSFKSVNTSV HIYDKAFITV KHRKQQVLET
VAGKRSYRLS MKVKAFPSPE VVWLKDGLPA TEKSARYLTR GYSLIKDVT
EEDAGNYTIL LSIKQSNVFK NLTATLIVNV KPQIYEKAVS SFPDPALYPL GSRQILTCTA
YGIPQPTIKW FWHPCNHNHS EARCDFCSNN EESFILDADS NMGNRIESIT
QRMAIIIEGKN KMASTLVVAD SRISGIYICI ASNKVGTVGR NISFYITDVP
NGFHVNLEKM PTEGEDLKLS CTVNKFLYRD VTWILLRTVN NRTMHYSISK
QKMAITKEHS ITLNLTIMNV SLQDSGTAC RARNVYTGEE ILQKKEITIR
DQEAPYLLRN LSDHTVAISS STTLDCHANG VPEPQITWFK NNHKIQQEPG
IILGPGSSTL FIERVTEEDE GVYHCKATNQ KGSVESSAYL TVQGTRSDKT
HTCPPCPAPE LLGGPSVFLF PPKPKDTLMI SRTPEVTCVV VDVSHEDPEV
KFNWYVDGVE VHNAKTKPRE EQYNSTYRVV SVLTVLHQDW LNGKEYKCKV
SNKALPAPIE KTISKAKGQP REPQVYTLPP SREEMTKNQV SLTCLVKGFY
PSDIAVEWES NGQPENNYKT TPPMLDSDGS FFLYSKLTVD KSRWQQGNVF
SCSVMHEALH NHYTQKSLSL SPGK

NOT FOR HUMAN USE. FOR RESEARCH ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE.

